CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 29 pages
RSV Vaccination in Adults: Work Group Interpretations Michael Melgar, MD Amadea Britton, MD, SMAdvisory Committee on Immunization PracticesOctober 24, 2024National Center for Immunization and Respiratory Diseases 2•Summarize Work Group interpretations of: - - -Current RSV vaccine safety surveillance data and the balance of estimated benefits and risks associated with protein subunit* RSV vaccination in adults ages 60 years and older Coadministration of RSV vaccines with other adult vaccines…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 9 pages
Recommendations from the Combined Immunization Schedule Work Group for the 2025 Immunization Schedules for Children/Adolescents and Adults Sybil Cineas, MD, FAAP , FACP (ACIP Combined Immunization WG Chair) Nanda Issa, MD ( CDC Co -Lead ) Patricia Wodi, MD (CDC acting Co -Lead) ACIP Meeting October 24, 2024National Center for Immunization and Respiratory Diseases The Combined Immunization Schedules WG: •Updates the immunization schedules annually -Child and adolescent schedule (for ages…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 34 pages
Recommendations from the Combined Immunization Schedule Work Group for the 2025 Immunization Schedules for Children/Adolescents and Adults Sybil Cineas, MD, FAAP , FACP (ACIP Combined Immunization WG Chair) Nanda Issa, MD (CDC Co -Lead ) Patricia Wodi, MD (CDC acting Co -Lead) ACIP Meeting October 24, 2024National Center for Immunization and Respiratory Diseases Dr. Nanda Issa2025 Update to Child and Adolescent Immunization Schedule Age 18 years or younger How to Use the Immunization…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 53 pages
Recommendations from the Combined Immunization Schedule Work Group for the 2025 Immunization Schedules for Children/Adolescents and Adults Sybil Cineas, MD, FAAP , FACP (ACIP Combined Immunization WG Chair) Nanda Issa, MD (CDC Co -Lead) Patricia Wodi, MD (CDC acting Co -Lead) ACIP Meeting October 24, 2024National Center for Immunization and Respiratory Diseases Dr. Patricia Wodi 2025 Update to Adult Immunization Schedule Age 19 years or older How to Use the Immunization Schedule Sections…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 9 pages
Introduction to the HPV Vaccines Work Group Oliver Brooks, MD Chair, HPV Vaccines Work Group Advisory Committee on Immunization Practices October 24, 2024 National Center for Immunization & Respiratory Diseases •HPV Vaccines Work Group re -formation announced at June 2024 ACIP meeting •An HPV Vaccines Work Group met previously for many years, but had been inactive since 2019 •3 meetings since July 2024Background 2 •Routine vaccination -Age 11 or 12 years -Can be started at age 9 years …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 48 pages
Introduction to policy considerations: Reduced number of HPV vaccine doses Lauri Markowitz, MD Co-Lead, HPV Vaccines Work Group Division of Viral Diseases Advisory Committee on Immunization Practices October 24, 2024National Center for Immunization & Respiratory Diseases ▪Brief introduction to human papillomavirus (HPV) ▪HPV vaccines and vaccination recommendations in the United States ▪Overview of data on vaccination with a reduced number of doses ▪World Health Organization recommendations…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 17 pages
Introduction to policy consideration: Wording of the age for routine vaccination Ruth Stefanos, MD, MPH LCDR, US Public Health Service Division of Viral Diseases Advisory Committee on Immunization Practices October 24, 2024National Center for Immunization and Respiratory Diseases 1 Outline •Current recommendation and historical context •Clinical Decision Support for Immunization project •Vaccination coverage •Interest in vaccination at age 9 years 2 Current Recommendation…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 23 pages
Human papillomavirus vaccination at age 9 or 10 years to increase coverage – a systematic review and narrative review of the literature Sarah Brewer, PhD, MPH Division of Viral Diseases Advisory Committee on Immunization Practices October 24, 2024 National Center for Immunization & Respiratory Diseases Background 2 •Since HPV vaccine was first licensed and recommended in 2006 for females, the wording of the routine age recommendation has remained the same •While HPV vaccination coverage…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 3 pages
HPV Vaccines Work Group – Next Steps Carla L. DeSisto, PhD, MPH Co-Lead, HPV Vaccines Work Group Advisory Committee on Immunization Practices October 24, 2024 National Center for Immunization & Respiratory Diseases •Number of doses in the recommended HPV vaccination series: -Started GRADE process, planning full Evidence to Recommendations ( EtR) framework -February 2025 ACIP meeting: plan to share additional data from trials/studies, modeling, and partial EtR •Wording of the age for routine…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 7 pages
ACIP material — 7 pages. CDC vaccine advisory committee document. Open the PDF to read.
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 19 pages
Clade I Mpox Outbreak: Situational UpdateCenters for Disease Control and Prevention Agam Rao, MD CAPT, U.S. Public Health Service Chief Medical Officer, Poxvirus and Rabies Branch ACIP meeting Oct 24, 2024 2Clade I MPXV: Countries known for decades to be endemicDemocratic Republic of the Congo (DRC), Central African Republic, Republic of Congo, Cameroon, Gabon •Exposure to infected wildlife •Person -to-person spread -Skin-to-skin contact (including intimate or sexual contact) -Direct…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 10 pages
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Adult Respiratory Syncytial Virus (RSV) Session Camille Kotton, MD Chair, Adult RSV Work Group Advisory Committee on Immunization Practices (ACIP) June 26, 2024…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 17 pages
RSVpreF Adult Clinical Development Update ACIP Meeting 26 June 2024Iona Munjal, MD 2Extending Adult IndicationBivalent Stabilized Prefusion F •Based on contemporary RSV A & RSV B strainsRSVpreF Adult Clinical Development Program Updates ABRYSVO® (Respiratory Syncytial Virus Vaccine) •≥60 years (RENOIR trial) Season 2 analyses •≥18 years at High Risk for RSV ( MONeT trial) •Real-world effectiveness dataAdditional Clinical Trial Data Indication for ABRYSVO Maternal Immunize pregnant women to…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 18 pages
CO-1 AREXVY (Adjuvanted RSVPreF3) 2-Year Update ACIP June 26, 2024 Susan Gerber, MD Medical Director GSK Presentation by GSK at ACIP June 26, 2024 CO-2 AREXVY Indications AREXVY now indicated for active immunization for prevention of lower respiratory tract disease (LRTD) caused by RSV in ▪Individuals ≥ 60 YOA ▪Individuals 50-59 YOA at increased risk for LRTD caused by RSV YOA: years of age FDA, 2024. AREXVY Prescribing Information (PI); https://www.fda.gov/media/167805/download (URL…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 24 pages
1 Update on Moderna’s RSV Vaccine, mRESVIA (mRNA -1345), in Adults ≥60 Years of Age Advisory Committee on Immunization Practices (ACIP) Rituparna Das, MD PhD June 26, 2024 2 Licensure of mRESVIA, Moderna’s RSV Vaccine (mRNA -1345) in United States ▪FDA approval obtained May 31, 2024 ▪Indication/Presentation ▪For active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older ▪Single dose…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 28 pages
Update: Rapid Cycle Analysis of RSV Vaccines in Older Adults Jim Donahue, PhD DVM Marshfield Clinic Research Institute Presented to the ACIP June 26, 2024 1 RSV RCA Interim Report – June 26, 2024 •Description of Vaccine Safety Datalink and RCA •Review of surveillance methods •Descriptive analysis •Sequential analysis ̶Immune thrombocytopenia (ITP) ̶Guillain -Barré syndrome (GBS) ̶Atrial fibrillation 2 Vaccine Safety Datalink 2024 * 3•Collaborative project between CDC and 13 integrated…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 19 pages
1 Evaluation of Guillain -Barré Syndrome (GBS) following Respiratory Syncytial Virus (RSV) Vaccination Among Adults 65 Years and Older Dr. Patricia Lloyd, ScM PhD Health Statistician Office of Biostatistics and Pharmacovigilance Center for Biologics Evaluation and Research U. S. Food & Drug Administration MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) Respiratory Syncytial Virus (RSV) Vaccine, Adults June 26 – 28, 2024 2 Outline •Introduction •Observed vs. Expected…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 52 pages
Effectiveness of adult respiratory syncytial virus (RSV) vaccines, 2023 –2024 Diya Surie, MD Coronavirus and Other Respiratory Viruses Division Centers for Disease Control and Prevention June 26, 2024National Center for Immunization and Respiratory Diseases This presentation has been corrected. See slides 5, 6, 30, and 32 for corrected slides. The original slides are included at the end of the presentation. •Purpose of randomized vaccine trials is to answer the question:Goal of…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 41 pages
Economic Analysis of RSV Vaccination in Adults 50 years and Older David W. Hutton, PhD, MS Associate Professor, Health Management and Policy, School of Public Health Associate Professor of Global Public Health, School of Public Health Associate Professor, Industrial and Operations Engineering, College of Engineering University of Michigan 1 Research Team University of Michigan •David Hutton, PhD •Lisa Prosser, PhD •Angela Rose, MPH •Christina Nyamuswa , MSCDC •Michael Melgar, MD •Amadea…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 37 pages
Risk-Benefit Analysis of RSV Vaccination in Older Adults David W. Hutton, PhD, MS Associate Professor, Health Management and Policy, School of Public Health Associate Professor of Global Public Health, School of Public Health Associate Professor, Industrial and Operations Engineering, College of Engineering University of Michigan 1This presentation has been corrected. See slides 13, 20, and 21 for corrected slides. The original slides are included at the end of the presentation. Disclaimer…